Stocktoria
Emergent BioSolutions Inc. EBS
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2006-11-15
Emergent BioSolutions Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $742.9M | $1.0B | $1.0B | $1.1B | $1.8B |
| Gross profit | — | — | $317.6M | $383.0M | $891.3M |
| R&D expense | $53.2M | $70.7M | $111.4M | $188.3M | $235.2M |
| SG&A expense | $186.1M | $308.0M | $368.4M | $339.5M | $348.7M |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M | $341.4M |
| Interest expense | — | — | $87.9M | $37.3M | $34.5M |
| Income tax | $30.2M | $47.7M | $29.3M | -$7.4M | $83.7M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M | $219.5M |
| EPS (diluted) | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 |
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M | $320.2M |
| Free cash flow | $156.8M | $35.8M | -$257.9M | -$149.9M | $96.1M |
| Cash & equivalents | $205.4M | $99.5M | $111.7M | $642.6M | $576.1M |
| Inventory | $343.4M | $311.7M | $328.9M | $350.7M | $350.8M |
| Total assets | $1.3B | $1.4B | $1.8B | $3.2B | $3.0B |
| Total liabilities | $796.0M | $906.9M | $1.2B | $1.8B | $1.3B |
| Shareholders' equity | $522.6M | $482.8M | $649.3M | $1.4B | $1.6B |
Source: SEC EDGAR filings · CIK 0001367644 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.